In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2′-deoxyuridine activated by hypoxic irradiation

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 2, 2004, Pages 397-402

  Shibamoto, Yuta ^a   Tachi, Yukihiro ^b   Tanabe, Kazuhito ^b   Hatta, Hiroshi ^b   Nishimoto, Sei Ichi ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

5 Fluoro 2 deoxyuridine; FdUrd; Hypoxia; Prodrug; Radiation; Radiation activated

Indexed keywords

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IRRADIATION; ONCOLOGY; RADIATION EFFECTS; SYNTHESIS (CHEMICAL);

RADIATION ENERGY;

TUMORS;

ANTINEOPLASTIC AGENT; FLOXURIDINE; FLOXURIDINE DERIVATIVE; FLUOROURACIL; OFU 101; OFU 104; OFU 105; OFU 106; OFU 107; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPATHOGENIC EFFECT; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPOXIC CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOCHEMISTRY;

EID: 0942289880     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.048     Document Type: Conference Paper

References (25)

1. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer 7-year follow-up of cancer and leukemia group B (CALGB) 8433 trial . J Natl Cancer Inst. 88:1997;1210-1215.
2. Huncharek M., Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma Results of a meta-analysis of 1,528 patients from six randomized trials . Am J Clin Oncol. 25:2002;219-223.
3. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17:1999;2692-2699.
4. Jeremic B., Shibamoto Y., Milicic B., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck A prospective randomized trial . J Clin Oncol. 18:2000;1458-1464.
5. Jeremic B., Shibamoto Y., Acimovic L., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for stage III non-small-cell lung cancer A randomized study . J Clin Oncol. 14:1996;1065-1070.
6. Poggi M.M., Kroog G.S., Russo A., et al. Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 54:2002;670-676.
7. Tishler R.B., Norris C.M. Jr, Colevas A.D., et al. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer. 95:2002;1472-1481.
8. Isaac N., Panzarella T., Lan A., et al. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma A well tolerated adjuvant regimen . Cancer. 95:2002;696-703.
9. Yamada M., Kudoh S., Fukuda H., et al. Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Br J Cancer. 87:2002;258-263.
10. Komaki R., Seiferheld W., Ettinger D., et al. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer Long-term follow-up of RTOG 92-04 . Int J Radiat Oncol Biol Phys. 53:2002;548-557.
11. Symon Z., Davis M., McGinn C.J., et al. Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer from the laboratory to the clinic . Int J Radiat Oncol Biol Phys. 53:2002;140-145.
12. Nishimoto S., Hatta H., Ueshima H., et al. 1-(5′-fluoro-6′- hydroxy-5′,6′-dihydrouracil-5′-yl)-5-fluorouracil, a novel N(1)-C(5)-linked dimer that releases 5-fluorouracil by radiation activation under hypoxic conditions. J Med Chem. 35:1992;2711-2712.
13. Shibamoto Y., Zhou L., Hatta H., et al. A novel class of antitumor prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFU001) that release 5-fluorouracil upon hypoxic irradiation. Jpn J Cancer Res. 91:2000;433-438.
14. Mori M., Hatta H., Nishimoto S. Stereoelectronic effect on one-electron reductive release of 5-fluorouracil from 5 fluoro-1-(2′-oxocycloalkyl) uracils as a new class of radiation-activated antitumor prodrugs. J Org Chem. 65:2001;4641-4647.
15. Shibamoto Y., Zhou L., Hatta H., et al. In vivo evaluation of a novel antitumor prodrug, I-(2′-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. Int J Radiat Oncol Biol Phys. 49:2001;407-413.
16. van Laar J.A.M., Rustum Y.M., Ackland S.P., et al. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer. 34:1998;296-306.
17. Corbett TH, Griswold DP Jr, Roberts BJ, et al. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 1977; 40 (5 Suppl): 2660-2680.
18. Houghton JA, Houghton PJ. On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice. Cancer 1980;45(5 Suppl.):1159-1167.
19. Iigo M., Nishikata K., Hoshi A. In vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin. Jpn J Cancer Res. 83:1992;392-396.
20. Bartkowski R., Berger M.R., Aguiar J.L. Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2′- deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model. J Cancer Res Clin Oncol. 111:1986;42-46.
21. 19F-NMR spectroscopy . J Cancer Res Clin Oncol. 117:1991;295-304.
22. Shibamoto Y., Nishimoto S., Mi F., et al. Evaluation of various types of new hypoxic cell sensitizers using the EMT6 single cell-spheroid-solid tumour system. Int J Radiat Biol. 52:1987;347-357.
23. Shibamoto Y., Yukawa Y., Tsutsui K., et al. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn J Cancer Res. 77:1986;908-915.
24. Shibamoto Y., Sasai K., Abe M. The radiation response of SCCVII tumor cells in C3H/He mice varies with the irradiation conditions. Radiat Res. 109:1987;352-354.
25. Shibamoto Y., Mimasu Y., Tachi Y., et al. Comparison of 5-fluorouracil and 5-fluoro-2′-deoxyuridine as an effector in radiation-activated prodrug. J Chemother. 14:2002;390-396.